Buse, Dawn C.
Krasenbaum, Lynda J.
Seminerio, Michael J.
Packnett, Elizabeth R.
Carr, Karen
Ortega, Mario
Driessen, Maurice T.
Funding for this research was provided by:
Teva Pharmaceuticals
Article History
Received: 20 September 2023
Accepted: 7 February 2024
First Online: 12 March 2024
Declarations
:
: Dawn C. Buse has received research and/or consulting funding from Allergan/Abbvie, Amgen, Biohaven, Collegium, Lilly, Lundbeck, and Teva Pharmaceutical Industries. Maurice T. Driessen, Lynda J. Krasenbaum, and Mario Ortega are employees of Teva Pharmaceutical Industries. Elizabeth R. Packnett is an employee of Merative (IBM Watson Health at the time the study was conducted), which was contracted by Teva Pharmaceutical Industries to conduct this study. Michael J. Seminerio and Karen Carr were employees of Teva Pharmaceutical Industries at the time of the study but have since left the company; they are currently employees of AbbVie.
: Ethical approval was not required for this study, as only existing health care claims were used, and therefore, the data do not meet the definition of human subject research. As this study did not involve human participants or the collection, use, or transmittal of individually identifiable data, institutional review board approval was not required. All data recorded on the databases were deidentified and fully compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996.